Loading...
XNASTXMD
Market cap12mUSD
Dec 27, Last price  
1.09USD
1D
0.00%
1Q
-33.54%
Jan 2017
-99.62%
Name

TherapeuticsMD Inc

Chart & Performance

D1W1MN
XNAS:TXMD chart
P/E
—
P/S
9.65
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
18.33%
Rev. gr., 5y
-39.53%
Revenues
1m
-98.14%
621,927934,5251,005,2740010,56948,2172,088,1773,818,0138,775,59815,026,21920,142,89819,356,45016,777,71316,099,46049,646,93764,872,28086,951,00069,963,0001,302,000
Net income
-10m
L
142,116289,887373,015170,542-395,553-1,654,541-695,375-12,913,365-35,120,235-28,419,313-54,217,210-85,077,024-89,875,459-76,925,380-132,617,160-196,027,320-212,702,827-205,604,000111,997,000-10,278,000
CFO
-48m
L+1,080.51%
207,727412,339329,840344,098-133,003-417,338836,832-4,966,596-12,737,326-20,768,069-45,520,996-79,044,119-69,142,333-76,155,614-106,811,781-165,697,595-159,470,335-142,693,000-4,078,000-48,141,000
Earnings
Mar 27, 2025

Profile

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
URL
https://www.therapeuticsmd.com/
IPO date
Jan 31, 2001
Employees
1
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,302
-98.14%
69,963
-19.54%
86,951
34.03%
Cost of revenue
59,300
226,721
Unusual Expense (Income)
NOPBT
1,302
10,663
(139,770)
NOPBT Margin
100.00%
15.24%
Operating Taxes
43
(91,862)
33,189
Tax Rate
3.30%
NOPAT
1,259
102,525
(172,959)
Net income
(10,278)
-109.18%
111,997
-154.47%
(205,604)
-3.34%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,151
(14,505)
184,115
BB yield
-13.41%
28.74%
-130.13%
Debt
Debt current
1,473
1,390
188,269
Long-term debt
13,064
16,128
16,126
Deferred revenue
Other long-term liabilities
636
1,107
2,139
Net debt
10,210
(40,802)
139,273
Cash flow
Cash from operating activities
(48,141)
(4,078)
(142,693)
CAPEX
(355)
(2,223)
Cash from investing activities
223,479
(2,223)
Cash from financing activities
3,151
(235,206)
129,552
FCF
(4,893)
109,149
(170,884)
Balance
Cash
4,327
38,067
65,122
Long term investments
20,253
Excess cash
4,262
54,822
60,774
Stockholders' equity
(949,630)
(939,354)
(1,050,930)
Invested Capital
987,558
984,363
1,155,780
ROIC
0.13%
9.58%
ROCE
3.43%
23.69%
EV
Common stock shares outstanding
10,441
9,028
7,960
Price
2.25
-59.75%
5.59
-68.55%
17.78
-70.62%
Market cap
23,492
-53.45%
50,467
-64.33%
141,489
-57.58%
EV
33,702
9,665
280,762
EBITDA
1,424
11,856
(135,677)
EV/EBITDA
23.67
0.82
Interest
32,917
Interest/NOPBT